Susquehanna Fundamental Investments LLC Buys New Shares in Insmed Incorporated (NASDAQ:INSM)

Susquehanna Fundamental Investments LLC bought a new position in Insmed Incorporated (NASDAQ:INSM) during the first quarter, according to the company in its most recent filing with the SEC. The firm bought 166,409 shares of the biopharmaceutical company’s stock, valued at approximately $4,515,000. Susquehanna Fundamental Investments LLC owned 0.11% of Insmed as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. International Assets Investment Management LLC bought a new position in shares of Insmed in the fourth quarter worth approximately $25,000. Fidelis Capital Partners LLC bought a new stake in Insmed during the 1st quarter valued at $34,000. Quarry LP purchased a new stake in Insmed during the 4th quarter valued at $116,000. Assetmark Inc. grew its holdings in Insmed by 23.3% in the 4th quarter. Assetmark Inc. now owns 5,915 shares of the biopharmaceutical company’s stock worth $183,000 after acquiring an additional 1,116 shares during the last quarter. Finally, QRG Capital Management Inc. purchased a new position in shares of Insmed in the fourth quarter valued at about $246,000.

Wall Street Analysts Forecast Growth

INSM has been the topic of a number of research reports. Wells Fargo & Company lifted their target price on shares of Insmed from $55.00 to $77.00 and gave the company an “overweight” rating in a research note on Wednesday, May 29th. The Goldman Sachs Group lifted their price objective on Insmed from $74.00 to $102.00 and gave the company a “buy” rating in a research report on Wednesday, July 10th. Bank of America reissued a “buy” rating and issued a $83.00 target price on shares of Insmed in a research report on Friday, July 5th. Guggenheim lifted their price target on Insmed from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. Finally, Mizuho increased their price objective on Insmed from $36.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, June 7th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $74.50.

Insider Buying and Selling at Insmed

In related news, insider John Drayton Wise sold 5,088 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $25.47, for a total transaction of $129,591.36. Following the completion of the transaction, the insider now directly owns 123,259 shares of the company’s stock, valued at $3,139,406.73. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, insider John Drayton Wise sold 5,088 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $25.47, for a total value of $129,591.36. Following the sale, the insider now directly owns 123,259 shares in the company, valued at approximately $3,139,406.73. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Martina M.D. Flammer sold 21,195 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $55.00, for a total transaction of $1,165,725.00. Following the sale, the insider now owns 106,134 shares in the company, valued at $5,837,370. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 295,842 shares of company stock worth $13,762,062. Insiders own 4.60% of the company’s stock.

Insmed Stock Performance

INSM traded up $0.16 during midday trading on Monday, reaching $76.87. The company had a trading volume of 840,735 shares, compared to its average volume of 2,592,291. The business has a 50-day moving average of $51.35 and a two-hundred day moving average of $35.98. Insmed Incorporated has a 1 year low of $20.16 and a 1 year high of $77.93.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.16. The firm had revenue of $75.50 million for the quarter, compared to analysts’ expectations of $77.76 million. The firm’s quarterly revenue was up 15.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.17) EPS. On average, analysts expect that Insmed Incorporated will post -4.71 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.